share_log

Axsome Therapeutics Plans to Refile New Drug Application for AXS-07 to Treat Migraine in Q3 of 2023; Shares Rise

Axsome Therapeutics Plans to Refile New Drug Application for AXS-07 to Treat Migraine in Q3 of 2023; Shares Rise

Axome治療公司計劃在2023年第三季度重新提交AXS-07治療偏頭痛的新藥申請;股價上漲
MT Newswires ·  2022/09/29 09:30

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論